miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
Authors:
Open Access
- 22 January 2013
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 5 (3) , 813-818
Abstract
Estrogen receptor‑α (ERα) is essential for estrogen‑dependent growth and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα‑positive breast cancer. Breast cancer patients show a wide range of ERα expression levels which change in individual patients during disease progression and in response to systemic therapies. However, little is known concerning how the expression of ERα is regulated in human breast cancer. Recently, several microRNAs (miRNAs) have been identified to regulate ERα expression and to predict ER, progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status. The expression levels of miR‑342 and ERα mRNA were analyzed in human breast cancer samples and cell lines by quantitative reverse transcription (RT)‑PCR analysis. The correlations between the expression levels of miR‑342 and clinicopathological factors were analyzed. Statistically significant associations were observed between miR‑342 and ER, HER2 and vascular endothelial growth factor (VEGF) status in the human breast cancer samples and the levels of miR‑342 gradually increased as ERα mRNA expression increased. Moreover, ectopic overexpression of miR‑342 upregulated the expression levels of the ERα mRNA and significantly sensitized the MCF‑7 cells to tamoxifen‑induced apoptosis and inhibition of cellular proliferation. These results suggested that miR‑342 expression is positively correlated with ERα mRNA expression in human breast cancer and that it may be a significant marker for predicting tamoxifen sensitivity in ERα‑positive breast cancer and a potential target for restoring ERα expression and responding to antiestrogen therapy.Keywords
This publication has 20 references indexed in Scilit:
- Downregulation of miR-342 is associated with tamoxifen resistant breast tumorsMolecular Cancer, 2010
- The widespread regulation of microRNA biogenesis, function and decayNature Reviews Genetics, 2010
- MicroRNA Cluster 221-222 and Estrogen Receptor α Interactions in Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNAMolecular and Cellular Biology, 2009
- MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neureceptor status in breast cancerBreast Cancer Research, 2009
- MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast CancerJournal of Biological Chemistry, 2008
- MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtypeGenome Biology, 2007
- The Micro-Ribonucleic Acid (miRNA) miR-206 Targets the Human Estrogen Receptor-α (ERα) and Represses ERα Messenger RNA and Protein Expression in Breast Cancer Cell LinesMolecular Endocrinology, 2007
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAsNature, 2005